| Literature DB >> 29430254 |
Mysrayn Y F A Reis1, Simone M Dos Santos2, Danielle R Silva2, Márcia V Silva3, Maria Tereza S Correia3, Daniela M A Ferraz Navarro4, Geanne K N Santos4, Fernando Hallwass4, Otávio Bianchi5, Alexandre G Silva6, Janaína V Melo7, Alessandra B Mattos8, Rafael M Ximenes6, Giovanna Machado8, Karina L A Saraiva9.
Abstract
Babassu oil extraction is the main income source in nut breakers communities in northeast of Brazil. Among these communities, babassu oil is used for cooking but also medically to treat skin wounds and inflammation, and vulvovaginitis. This study aimed to evaluate the anti-inflammatory activity of babassu oil and develop a microemulsion system with babassu oil for topical delivery. Topical anti-inflammatory activity was evaluated in mice ear edema using PMA, arachidonic acid, ethyl phenylpropiolate, phenol, and capsaicin as phlogistic agents. A microemulsion system was successfully developed using a Span® 80/Kolliphor® EL ratio of 6 : 4 as the surfactant system (S), propylene glycol and water (3 : 1) as the aqueous phase (A), and babassu oil as the oil phase (O), and analyzed through conductivity, SAXS, DSC, TEM, and rheological assays. Babassu oil and lauric acid showed anti-inflammatory activity in mice ear edema, through inhibition of eicosanoid pathway and bioactive amines. The developed formulation (39% A, 12.2% O, and 48.8% S) was classified as a bicontinuous to o/w transition microemulsion that showed a Newtonian profile. The topical anti-inflammatory activity of microemulsified babassu oil was markedly increased. A new delivery system of babassu microemulsion droplet clusters was designed to enhance the therapeutic efficacy of vegetable oil.Entities:
Year: 2017 PMID: 29430254 PMCID: PMC5753019 DOI: 10.1155/2017/3647801
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Physicochemical parameters of babassu oil from Chapada do Araripe, Brazil.
| Physicochemical parameters | Babassu oil (unrefined) | Reference value (refined oil) |
|---|---|---|
| Relative density (g/mL) | 0.9210 | 0.9140–0.9170 |
| Refractive index at 40°C | 1.458 | 1.448–1.451 |
| Acid value (mgKOH/g) | 0.13 | Max. 4 |
| Peroxide value (meq/kg) | nd | Max. 15 |
| Rancidity | Absent | Absent |
nd: not detected.
Fatty acid composition of babassu oil from Chapada do Araripe, Brazil.
| Skeleton | Compound | Area (%) ± St Dev |
|---|---|---|
| C12:0 | Dodecanoic acid | 40.78 ± 1.56 |
| C13:0 | Tridecanoic acid | 0.03 ± 0.01 |
| C14:0 | Tetradecanoic acid | 20.05 ± 0.27 |
| C16:0 | Hexadecanoic acid | 12.26 ± 0.59 |
| C18:2n6c | (Z,Z)-9,12-Octadecadienoic acid | 2.39 ± 0.29 |
| C18:1n9c | (Z)-9-Octadecenoic acid | 21.35 ± 0.36 |
| C18:0 | Octadecanoic acid | 2.64 ± 0.09 |
1H and 13C NMR chemical shift (δ) data of babassu oil in CDCl3.
| Hydrogen |
| Carbon |
|
|---|---|---|---|
| C | 5.33 |
| 173.2 and 172.8 |
| C | 5.22 |
| 129.9 and 129.6 |
| C | 4.29 |
| 62.1 |
| C | 4.15 |
| 68.8 |
| C=C-C | 2.74 | C=C- | 27.2 |
| C | 2.30 |
| 34.1 |
| C | 2.01 |
| 31.8 |
| C | 1.61 |
| 24.8 |
|
| 1.28 |
| 22.6 |
| CH3 | 0.87 |
| 29.7–28.8 |
|
| 14.0 |
Figure 1(a) Topical and (b) systemic anti-inflammatory activity of babassu oil in PMA-induced ear edema. Results are expressed as the mean ± SEM and analyzed by ANOVA followed by Tukey's test with p set at 0.05. Different letters show statistical differences between groups (p < 0.05). (−) Negative control (acetone); babassu oil (μL/ear in (a)) and (mg/kg, p.o. in (b)); (LA) lauric acid (mg/ear); (Dexa) dexamethasone (mg/ear), and (Indo) indomethacin (mg/kg, p.o.).
Figure 2Topical anti-inflammatory activity of babassu oil and lauric acid in (a) arachidonic acid; (b) ethyl phenylpropiolate; and (c) phenol-induced ear edema. Results are expressed as the mean ± SEM and analyzed by ANOVA followed by Tukey's test with p set at 0.05. Different letters show statistical differences between groups (p < 0.05). (−) Negative control (acetone); (BA) babassu oil (μL/ear); (LA) lauric acid (mg/ear); (Indo) indomethacin (mg/ear); and (Dexa) dexamethasone (mg/ear).
Figure 3Pseudo-ternary phase diagram (8 : 2) of the babassu oil microemulsion. The black region includes the microemulsion systems (ME) and the selected formulation (white dot). OLE, opaque liquid emulsions; MLE, milk liquid emulsions.
Figure 4The ultrastructure of the babassu microemulsion that shows clusters of nanodroplets filled with oil, some of which have merged with one another and are surrounded by the surfactant interface and aqueous phase.
Figure 5(a) Scattering intensity I of the SAXS measurements as a function of the scattering vector q for the babassu oil microemulsion. The solid line is the fit according to supplementary file procedure (Equation (S1)). The spherical shell had an average outer radius of R = 8.7 nm and inner radius of vR = 3.48 ± 0.02 nm. The normalized size distribution P(r) as a function of the overall radius (R) is also shown. (b) Structure factor S(q) for a hard sphere interaction potential of the babassu microemulsion with an average correlation distance (RHS) of 12 ± 0.01 nm and a volume fraction of 0.14 ± 0.001.
Figure 6DSC thermographs for the babassu microemulsion, showing a broad endothermic melt transition in two temperature regions (inset).
Figure 7Topical anti-inflammatory activity of babassu oil and microemulsion in PMA-induced ear edema. Results are expressed as the mean ± SEM and analyzed by ANOVA followed by Tukey's test with p set at 0.05. Different letters show statistical differences between groups (p < 0.05). (−) Negative control (acetone); (V) microemulsion vehicle (48.8% surfactants, 39% aqueous phase, and 12.2% water); babassu oil (μL/ear); (ME) babassu microemulsion (μL/ear); and (Dexa) dexamethasone (mg/ear).